Shares of Tilray fell as much as 4% Tuesday after the company reported its second-quarter earnings, which beat expectations for revenue but showed a larger-than-expected loss.

Here's what the company reported versus what analysts surveyed by Bloomberg had expected:

  • Adjusted loss per share: -$0.32 per share reported versus -$0.26 per share (expected)
  • Revenue: $45.9 million reported versus $40.34 million (expected)

Revenue for the quarter increased 371% year-on-year, driven by the acquisition of Manitoba Harvest, the legalization of adult-use cannabis in Canada, and growth in international medical markets, the company said.

Still, the company reported an adjusted loss of $31.2 million for the second quarter, nearly triple losses in the same quarter last year. The loss was attributed to increased operating expenses related to growth.

"We are pleased with our second quarter results and strong business momentum," saidBrendan Kennedy,Tilray's CEO, in a press release . "Our team has executed against our plan, with adult-use revenue nearly doubling in the second quarter compared to the first quarter and gross margin increasing sequentially for the second quarter in a row. As we continue to grow, we remain focused on our long-term strategic objectives and deploying capital to maximize stockholder value."

While Tilray was the first cannabis company to go public in the US, its share price has slipped from a high of more than $200 last September to where it currently trades around $45.

In March, shares rose after the company reported first-quarter earnings that exceeded sales expectations but missed on the bottom line.

Analysts are wary of the company partly because it has broadened its focus from Canada to international markets a move that industry watchers have called risky.

"Tilray is NOT a story of growth in Canada or with production that really matters overall," wrote Tim Seymour, portfolio manager of the Amplify Seymour Cannabis ETF. "They are lagging the big LPs in Canada" including Canopy Growth, Aphria, Aurora and Organigram.

Other analysts agree. The Canadian adult-use market provides some opportunity for Tilray, wrote W. Andrew Carter of Stifel in a note Tuesday. However, the company "faces a later start to the Canadian second wave and still faces a lack of regulatory clarity from the FDA around CBD," Carter added.

This could keep the company from launching its US CBD products during 2019, Carter wrote.

In February, Tilray purchased Manitoba Harvest , the world's largest hemp-food company, for $318 million. Hemp is largely used because it contains cannabidiol or CBD, which is estimated to become a $16 billion market in the US by 2025. The company purchased Manitoba Harvest to develop hemp-derived CBD food and wellness products to be released in the US and Canada.

Wall Street is largely neutral on the company 11 analysts have a hold rating on the stock, two say sell, and five say to buy. The average 12-month price target is $70.00.

Shares of Tilray are down roughly 35% year-to-date.

Screen Shot 2019 08 13 at 4.23.30 PM
Screen Shot 2019 08 13 at 4.23.30 PM
Markets Insider

NOW WATCH: What El Chapo is really like, according to the wife of one his closest henchman

See Also: